Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows
Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.
Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.
The STaR study compared Complera to Atripla and found that Complera was not only non-inferior to Atripla, it performed better in terms of HIV symptoms and quality of life.
A new study finds that black people are less likely to keep their viral load down on Atripla -- and that more trouble with side effects may be the reason.
Seattle, Wash. -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced full Phase 3 clinical trial results from pivotal Study 102 demonstrating that the Quad, a once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir...
Gerald Pierone Jr., M.D.
Atripla (which is a combination of efavirenz + tenofovir + emtricitabine) is the acknowledged king in the realm of first-line antiretroviral therapy. Le Roi est mort, vive le Roi! Not so fast: The king still breathes. But ...